What happens on the day of your ChondroFiller hip injection

For most patients, the answer to the first question they ask is yes — you will walk out of the clinic on the same day.

The ChondroFiller hip injection is an outpatient, ultrasound-guided procedure carried out under local anaesthesia. There is no theatre admission, no general anaesthetic, and no surgical wound. The collagen scaffold is placed into the cartilage defect via a percutaneous injection — guided precisely by live imaging — rather than through arthroscopy or keyhole surgery.

Once positioned in the joint, the scaffold gels within approximately 3–5 minutes by bonding with natural fibrin already present in the hip. The structural matrix is dimensionally stable before you leave the appointment. From that point, the scaffold begins its biological role: recruiting the body's own progenitor cells from the surrounding synovium and subchondral bone to support repair through acellular matrix-induced chondrogenesis.

For the first 24–48 hours, mild joint 'fullness', localised soreness, or some stiffness is a normal response and typically settles on its own. Over-the-counter paracetamol or an NSAID can manage early discomfort. The more structured rehabilitation phase — including a period of protected weight-bearing — begins in the days that follow.

The first 48 hours: normal reactions and how to manage them

The reactions arise from the joint's natural response to both the needle entry and the scaffold itself. Introducing any substance into a synovial joint prompts a brief, localised inflammatory response: synovial fluid volume may increase slightly, the surrounding soft tissues can feel irritated, and the musculature sometimes tightens as a protective reflex. None of this signals a complication — it reflects a joint beginning to engage with the new matrix.

Analgesic needs during this window are typically modest. Keeping the hip held in one position for long periods tends to intensify stiffness rather than relieve it; short, gentle walks on flat ground help maintain circulation without placing significant load on the joint. Sustained rest in a chair or bed is not recommended.

Most of these reactions settle within 48 hours. Contact the clinic promptly if pain becomes severe, swelling is markedly beyond the expected joint fullness, or a fever develops — these presentations are uncommon, but they warrant clinical review rather than home management alone.

Weeks 1–6: protected movement, not bed rest

The crutches prescribed at discharge are not a precaution against pain — they are structural protection for the scaffold now sitting inside your hip joint.

During the first six weeks, the collagen matrix is at its most mechanically vulnerable. Progenitor cells from the surrounding synovium and subchondral bone are migrating into the scaffold, but that cellular anchoring takes days to weeks to establish. A 2024 biomechanical study found that cyclic loading applied before this migration is secure risks destabilising the gel, potentially disrupting the matrix before it can begin supporting repair. Using crutches to offload approximately 5–20 kg of body weight keeps joint forces below the threshold that would compromise that early scaffold integrity.

What this phase is not is bed rest. Controlled, gentle movement — short walks on flat ground, careful weight-shifting through the hip — actively supports recovery by maintaining circulation to the joint and preventing the muscle weakness and stiffness that follow immobility. The goal throughout is protection from excessive load, not from movement itself.

Stairs and uneven terrain introduce unpredictable shear forces and should be avoided for the full six weeks. It is worth planning your home and working environment before the procedure so that ground-floor access and flat routes are available from day one.

At around the six-week mark, a clinical review assesses how the joint is progressing. For most patients this marks the beginning of a gradual transition toward fuller weight-bearing — not a fixed clearance date, but a milestone at which the clinician can judge whether the next phase is appropriate.

Weeks 6–12: from protected walking to independent movement

For most patients, the six-week review marks a turning point rather than a finish line. Assuming the joint has responded as expected, the clinician will agree a gradual reduction in crutch use — not an immediate return to full loading, but a deliberate, week-by-week shift. Most patients complete that transition and move to unaided walking by weeks 6–8.

The three-month mark is when independent walking on flat ground tends to move from 'possible' to genuinely comfortable. Months 3–4 represent the window cited by clinical sources as the point where everyday movement — the kind patients typically lost before seeking treatment — returns without significant discomfort. That distinction matters practically: being able to walk without support is not the same as finding it pain-free and sustainable across a normal day.

Individual variation is real and worth planning around. Defect size, the condition of the surrounding cartilage, and how efficiently a patient's own progenitor cells populate the scaffold all influence pace. Physiotherapy during this phase — focused on restoring hip muscle strength and stability — directly supports the transition and should not be treated as optional.

The six-week review is a shared clinical decision, not automatic progression. Patients who are not yet ready will continue with protected weight-bearing until a subsequent assessment confirms the joint is prepared for the next stage.

Months 3–12: returning to exercise and higher-demand activity

Scaffold maturation inside the hip continues for up to 12–24 months after injection. The collagen matrix is gradually resorbed and replaced by the patient's own cartilage-like tissue through acellular matrix-induced chondrogenesis — a process still under way long after walking becomes comfortable again. That timeline shapes the rest of the activity progression.

Months 3–6: introducing low-impact exercise

Cycling, swimming, and targeted hip-strengthening exercises are typically introduced during this window. These activities load the joint progressively without the impact spikes that could stress a still-maturing scaffold, while building the muscular support needed for more demanding movement later.

Months 6–12: working toward higher-demand activity

Running, jogging, and contact sport should wait until approximately one year post-procedure. The repair matrix needs that full period to reach the structural resilience required for repetitive high-load cycles. Returning too early risks loading tissue that may feel stable but is not yet biomechanically prepared.

Long-term outcomes and patient selection

The prospective hip cohort published by Mazek et al. (2021) — 26 patients treated for acetabular defects greater than 2 cm² — found 17 out of 21 achieved good or excellent results at three to five years, with MRI confirming cartilage healing. That study used arthroscopic delivery rather than the outpatient injection pathway; it serves as background context and the clearest available clinical benchmark for hip ChondroFiller repair outcomes. Across the broader published evidence base, 70–85% of patients achieve meaningful symptom relief at three to five years.

One finding carries a direct patient-selection implication: individuals with Tönnis grade 2–3 pre-existing osteoarthritis had poor results in that cohort. Baseline joint condition is a primary determinant of outcome — which is why a thorough clinical assessment before treatment is not a formality.

What influences your result — and next steps

Three factors consistently separate patients who do well from those who do not: the size and depth of the cartilage defect at the time of treatment, the condition of the surrounding joint, and how closely the rehabilitation programme is followed during the critical first six months.

Hip-specific data from percutaneous injection trials remains limited — the published cohort evidence is drawn predominantly from arthroscopic delivery and knee studies. Recovery milestones throughout this article follow established clinical protocols rather than a large injection-route hip RCT. That context translates into one practical question worth raising at any assessment: ask the clinician how outcomes in their injection-route hip patients compare with the published arthroscopic cohort. A direct answer from someone experienced in this specific delivery route will be more informative than the literature headline in isolation.

Across more than 19,000 global cases, ChondroFiller's safety profile is well established. The treatment is not routinely NHS-funded; guide costs vary and should be confirmed directly with the treating clinic.

An assessment at the London Cartilage Clinic on Harley Street will clarify whether your defect size and joint condition fall within the treatment's indication, and what a realistic outcome looks like for your specific hip. Book via londoncartilage.com.